Cefiderocol Versus Best Available Therapy in the Treatment of Critically Ill Patients with Severe Infections Due to Resistant Gram-Negative Bacteria: A Systematic Review and Meta-Analysis

Carlos Risco-Risco, César Henriquez-Camacho, Marta Herrera-Rueda, José Barberán, David Andaluz-Ojeda

Open source

DOI
10.3390/antibiotics13111048
Published
2024-11-05
Container
Antibiotics
Publisher
MDPI AG
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/antibiotics13111048,
  title = {Cefiderocol Versus Best Available Therapy in the Treatment of Critically Ill Patients with Severe Infections Due to Resistant Gram-Negative Bacteria: A Systematic Review and Meta-Analysis},
  author = {Carlos Risco-Risco and César Henriquez-Camacho and Marta Herrera-Rueda and José Barberán and David Andaluz-Ojeda},
  year = {2024},
  journal = {Antibiotics},
  doi = {10.3390/antibiotics13111048},
  url = {https://doi.org/10.3390/antibiotics13111048}
}

RIS

TY  - JOUR
TI  - Cefiderocol Versus Best Available Therapy in the Treatment of Critically Ill Patients with Severe Infections Due to Resistant Gram-Negative Bacteria: A Systematic Review and Meta-Analysis
AU  - Carlos Risco-Risco
AU  - César Henriquez-Camacho
AU  - Marta Herrera-Rueda
AU  - José Barberán
AU  - David Andaluz-Ojeda
PY  - 2024
JO  - Antibiotics
DO  - 10.3390/antibiotics13111048
UR  - https://doi.org/10.3390/antibiotics13111048
ER  - 

APA

Risco-Risco, C., Henriquez-Camacho, C., Herrera-Rueda, M., Barberán, J., & Andaluz-Ojeda, D. (2024). Cefiderocol Versus Best Available Therapy in the Treatment of Critically Ill Patients with Severe Infections Due to Resistant Gram-Negative Bacteria: A Systematic Review and Meta-Analysis. Antibiotics. https://doi.org/10.3390/antibiotics13111048

Source records